Atomo NewsGet the app

Get the latest Science News and Discoveries

Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC


None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of NSCLC

NSCLC

Photo of phase

phase

Photo of Progression

Progression

Related news:

News photo

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC

News photo

Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC

News photo

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

« Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC
Drug decriminalization in BC reduced police encounters for drug possession, with no changes in drug-related deaths »